DK1959991T3 - Terapeutisk vaccine - Google Patents

Terapeutisk vaccine

Info

Publication number: DK1959991T3
Authority: DK; Denmark
Prior art keywords: therapeutic vaccine; vaccine; therapeutic
Prior art date: 2005-12-12

Application number

DK06829455.2T

Other languages

English (en)

Inventor

Andrea Pfeifer

Claude Nicolau

Original Assignee

Ac Immune Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-12

Filing date

2006-12-08

Publication date

2013-06-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1959991(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-12-08 Application filed by Ac Immune Sa filed Critical Ac Immune Sa

2013-06-17 Application granted granted Critical

2013-06-17 Publication of DK1959991T3 publication Critical patent/DK1959991T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Zoology (AREA)

DK06829455.2T 2005-12-12 2006-12-08 Terapeutisk vaccine DK1959991T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05027091		2005-12-12
EP06009098		2006-05-02
PCT/EP2006/011861 WO2007068411A2 (en)	2005-12-12	2006-12-08	Therapeutic vaccine

Publications (1)

Publication Number	Publication Date
DK1959991T3 true DK1959991T3 (da)	2013-06-17

Family

ID=37836865

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06829455.2T DK1959991T3 (da)	2005-12-12	2006-12-08	Terapeutisk vaccine

Country Status (24)

Country	Link
US (2)	US7807175B2 (da)
EP (2)	EP1959991B1 (da)
JP (2)	JP5249043B2 (da)
KR (2)	KR101236611B1 (da)
CN (1)	CN101330923B (da)
AR (1)	AR058327A1 (da)
AU (1)	AU2006326283B2 (da)
BR (1)	BRPI0619747B8 (da)
CA (1)	CA2633399C (da)
CR (1)	CR9994A (da)
DK (1)	DK1959991T3 (da)
EC (1)	ECSP088531A (da)
ES (2)	ES2407429T3 (da)
HK (1)	HK1127486A1 (da)
IL (1)	IL191397A (da)
MA (1)	MA30252B1 (da)
MY (1)	MY181173A (da)
NO (1)	NO346055B1 (da)
NZ (1)	NZ568384A (da)
RU (2)	RU2440824C2 (da)
SG (1)	SG172617A1 (da)
TW (1)	TWI537000B (da)
WO (1)	WO2007068411A2 (da)
ZA (1)	ZA200804918B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2527661T3 (es)	2005-11-30	2015-01-28	Abbvie Inc.	Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
PL1976877T5 (pl)	2005-11-30	2017-09-29	Abbvie Inc	Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
ES2892925T3 (es)	2006-03-31	2022-02-07	Chugai Pharmaceutical Co Ltd	Métodos para controlar la farmacocinética en sangre de anticuerpos
EP2102165A2 (en)	2006-11-24	2009-09-23	AC Immune S.A.	N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en)	2007-02-27	2010-12-09	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
DK2142514T3 (da)	2007-04-18	2015-03-23	Probiodrug Ag	Thioureaderivater som glutaminylcyclase-inhibitorer
ES2595638T3 (es)	2007-09-26	2017-01-02	Chugai Seiyaku Kabushiki Kaisha	Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
EP2106802A1 (en)	2008-04-02	2009-10-07	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Modified peptides as synthetic vaccines in amyloid-associated disease
NZ602884A (en)	2008-04-11	2014-08-29	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010059253A2 (en)	2008-11-24	2010-05-27	Massachusets Institute Of Technology	Methods and compositions for localized agent delivery
SI2408807T1 (sl) *	2009-03-18	2021-11-30	Ac Immune Sa	Postopek za terapevtsko uporabo
UA107571C2 (xx) *	2009-04-03	2015-01-26		Фармацевтична композиція
KR100929372B1 (ko) *	2009-05-22	2009-12-02	고려대학교 산학협력단	아밀로이드 베타 단편을 유효성분으로 포함하는 돌연변이 ｓｏｄ1에 의한 ａｌｓ 예방 및 치료용 조성물
AT508638B1 (de) *	2009-08-21	2011-08-15	Affiris Ag	Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PL2475428T3 (pl)	2009-09-11	2015-12-31	Probiodrug Ag	Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2311823A1 (en)	2009-10-15	2011-04-20	AC Immune S.A.	2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2542549B1 (en)	2010-03-03	2016-05-11	Probiodrug AG	Inhibitors of glutaminyl cyclase
EP2545047B9 (en)	2010-03-10	2015-06-10	Probiodrug AG	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2547327B1 (en)	2010-03-19	2018-09-05	Massachusetts Institute of Technology	Lipid vesicle compositions and methods of use
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
CA2796339C (en)	2010-04-15	2020-03-31	Abbott Laboratories	Amyloid-beta binding proteins
US20110256064A1 (en)	2010-04-16	2011-10-20	Ac Immune, S.A.	Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
JP5911470B2 (ja)	2010-04-16	2016-04-27	エーシー・イミューン・エス・アー	アミロイドまたはアミロイド様タンパク質と関連する疾患を治療するための新規化合物
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
EP3527220A1 (en)	2010-08-12	2019-08-21	AC Immune S.A.	Vaccine engineering
CA2808187A1 (en)	2010-08-14	2012-02-23	Abbvie Inc.	Amyloid-beta binding proteins
CA2813833C (en)	2010-10-26	2020-09-22	Ac Immune S.A.	Liposome-based construct comprising a peptide modified through hydrophobic moieties
TWI654203B (zh)	2010-11-30	2019-03-21	中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
US20120148542A1 (en)	2010-12-10	2012-06-14	Lifeline Scientific, Inc.	Machine perfusion with complement inhibitors
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
GB201113570D0 (en)	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
KR20160005380A (ko) *	2011-09-23	2016-01-15	에이씨 이뮨 에스.에이.	백신 요법
AU2013243861A1 (en)	2012-04-05	2014-10-23	Ac Immune S.A.	Humanized Tau antibody
MX374811B (es)	2013-03-15	2025-03-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
WO2015048498A2 (en)	2013-09-27	2015-04-02	Massachusetts Institute Of Technology	Carrier-free biologically-active protein nanostructures
WO2015095780A1 (en) *	2013-12-20	2015-06-25	The University Of Kansas	Toll-like receptor 8 agonists
TWI617580B (zh)	2014-12-19	2018-03-11	中外製藥股份有限公司	抗ｃ５抗體及使用方法
EP3240804A4 (en)	2014-12-19	2019-01-09	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
US11034752B2 (en)	2015-08-12	2021-06-15	Massachusetts Institute Of Technology	Cell surface coupling of nanoparticles
EP3468581A1 (en)	2016-06-13	2019-04-17	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
JP6527643B2 (ja)	2016-08-05	2019-06-05	中外製薬株式会社	Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018081085A1 (en)	2016-10-25	2018-05-03	The Regents Of The University Of California	Methods of diagnosis and treatment of alzheimer's disease
US11389465B2 (en)	2017-05-01	2022-07-19	Vanderbilt University	Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections
JP7285828B2 (ja)	2017-09-05	2023-06-02	トルクセラピューティクス，インコーポレイテッド	治療用タンパク質組成物ならびにその作製および使用方法
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa
KR102710762B1 (ko)	2017-10-25	2024-09-25	얀센 파마슈티칼즈, 인코포레이티드	인산화 타우 펩티드의 조성물 및 이의 용도
CN108037277A (zh) *	2017-12-07	2018-05-15	中国兽医药品监察所	一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
CN112165956A (zh) *	2018-04-10	2021-01-01	Ac免疫有限公司	抗Aβ治疗性疫苗
MA52180A (fr)	2018-04-10	2021-02-17	Ac Immune Sa	Vaccins thérapeutiques anti-abêta
US12016885B2 (en)	2018-11-06	2024-06-25	Alsatech, Inc.	Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
JOP20210211A1 (ar)	2019-02-08	2023-01-30	Janssen Pharmaceuticals Inc	طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
BR112021021213A2 (pt)	2019-04-24	2021-12-21	Ac Immune Sa	Administração heteróloga de vacinas de tau
CA3138145A1 (en) *	2019-05-21	2020-11-26	Andrea Pfeifer	Anti-abeta vaccine therapy
WO2021207303A1 (en) *	2020-04-07	2021-10-14	Alsatech, Inc.	Immune stimulation against coronavirus infections
WO2024156912A1 (en)	2023-01-26	2024-08-02	Ac Immune Sa	Anti-abeta vaccine therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4847082A (en)	1987-01-21	1989-07-11	Robert Sabin	Method of treatment of Alzheimer's disease using phytic acid
US5262332A (en) *	1989-04-05	1993-11-16	Brigham And Women's Hospital	Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US6787523B1 (en) *	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
CA2388559A1 (en) *	1999-11-29	2001-06-07	Neurochem Inc.	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
DE10003992A1 (de) *	2000-01-29	2001-08-09	Bosch Gmbh Robert	Sensoranordnung
EP2305822A3 (en)	2000-09-06	2013-11-06	Aventis Pharma S.A.	Methods and compositions for diseases associated with Amyloidosis
EP1203614A1 (de)	2000-11-03	2002-05-08	Polymun Scientific Immunbiologische Forschung GmbH	Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CA2488230C (en) *	2002-04-29	2013-04-09	Yves Claude Nicolau	Inositol pyrophosphates, and methods of use thereof
JP2006525226A (ja)	2002-12-24	2006-11-09	ニューロケム（インターナショナル）リミテッド	β−アミロイド関連疾患の治療のための治療用製剤
US7521481B2 (en) *	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
US7884188B2 (en) *	2003-06-02	2011-02-08	Varleigh Immuno Pharmaceuticals (Vip) Ltd	Complement inhibitors
US20050123553A1 (en) *	2003-07-30	2005-06-09	Alon Monsonego	Amyloid beta-peptide and methods of use
CA2589017A1 (en) *	2004-12-15	2006-06-22	Neuralab Limited	Amyloid beta antibodies for use in improving cognition
EP1676859A1 (en) *	2004-12-30	2006-07-05	Pevion Biotech Ltd.	Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
EP2361638B1 (en) *	2005-12-12	2014-01-15	AC Immune S.A.	A beta 1-42 specific monoclonal antibodies with therapeutic properties

2006
- 2006-12-08 NZ NZ568384A patent/NZ568384A/en unknown
- 2006-12-08 JP JP2008544833A patent/JP5249043B2/ja active Active
- 2006-12-08 DK DK06829455.2T patent/DK1959991T3/da active
- 2006-12-08 KR KR1020127002472A patent/KR101236611B1/ko active Active
- 2006-12-08 MY MYPI20081951A patent/MY181173A/en unknown
- 2006-12-08 WO PCT/EP2006/011861 patent/WO2007068411A2/en active Application Filing
- 2006-12-08 ES ES06829455T patent/ES2407429T3/es active Active
- 2006-12-08 CA CA2633399A patent/CA2633399C/en active Active
- 2006-12-08 EP EP06829455A patent/EP1959991B1/en active Active
- 2006-12-08 BR BRPI0619747A patent/BRPI0619747B8/pt active IP Right Grant
- 2006-12-08 ES ES11172818.4T patent/ES2551604T3/es active Active
- 2006-12-08 CN CN200680046697.XA patent/CN101330923B/zh active Active
- 2006-12-08 SG SG2011036969A patent/SG172617A1/en unknown
- 2006-12-08 KR KR1020087017128A patent/KR101152557B1/ko active Active
- 2006-12-08 EP EP11172818.4A patent/EP2380588B1/en active Active
- 2006-12-08 AU AU2006326283A patent/AU2006326283B2/en active Active
- 2006-12-08 NO NO20082216A patent/NO346055B1/no unknown
- 2006-12-08 RU RU2008128133/15A patent/RU2440824C2/ru active
- 2006-12-12 US US11/637,607 patent/US7807175B2/en active Active
- 2006-12-12 TW TW095146547A patent/TWI537000B/zh active
- 2006-12-12 AR ARP060105476A patent/AR058327A1/es not_active Application Discontinuation
2008
- 2008-05-13 IL IL191397A patent/IL191397A/en active IP Right Grant
- 2008-05-20 CR CR9994A patent/CR9994A/es not_active Application Discontinuation
- 2008-06-05 ZA ZA2008/04918A patent/ZA200804918B/en unknown
- 2008-06-12 EC EC2008008531A patent/ECSP088531A/es unknown
- 2008-07-11 MA MA31115A patent/MA30252B1/fr unknown
2009
- 2009-04-14 US US12/386,140 patent/US8603487B2/en active Active
- 2009-06-09 HK HK09105160.4A patent/HK1127486A1/xx unknown
2011
- 2011-10-12 RU RU2011141308/15A patent/RU2011141308A/ru not_active Application Discontinuation
2013
- 2013-02-13 JP JP2013025108A patent/JP2013126993A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP5249043B2 (ja)	2013-07-31
JP2009519915A (ja)	2009-05-21
EP2380588A1 (en)	2011-10-26
ES2407429T3 (es)	2013-06-12
NO20082216L (no)	2008-08-22
JP2013126993A (ja)	2013-06-27
TWI537000B (zh)	2016-06-11
CN101330923A (zh)	2008-12-24
US20080267986A1 (en)	2008-10-30
IL191397A (en)	2016-05-31
ZA200804918B (en)	2011-10-26
HK1127486A1 (en)	2009-09-25
CN101330923B (zh)	2015-01-07
EP2380588B1 (en)	2015-08-05
AR058327A1 (es)	2008-01-30
CA2633399A1 (en)	2007-06-21
MY181173A (en)	2020-12-21
RU2011141308A (ru)	2013-04-20
ES2551604T3 (es)	2015-11-20
KR101152557B1 (ko)	2012-09-07
BRPI0619747B1 (pt)	2019-03-26
BRPI0619747B8 (pt)	2021-05-25
KR20120061049A (ko)	2012-06-12
KR101236611B1 (ko)	2013-03-04
AU2006326283B2 (en)	2012-01-19
EP1959991B1 (en)	2013-03-20
WO2007068411A2 (en)	2007-06-21
WO2007068411A3 (en)	2007-08-23
CA2633399C (en)	2016-01-26
BRPI0619747A2 (pt)	2011-10-18
CR9994A (es)	2008-09-22
SG172617A1 (en)	2011-07-28
TW200744630A (en)	2007-12-16
EP1959991A2 (en)	2008-08-27
AU2006326283A1 (en)	2007-06-21
US20090238840A1 (en)	2009-09-24
RU2440824C2 (ru)	2012-01-27
NO346055B1 (no)	2022-01-24
RU2008128133A (ru)	2010-01-20
KR20080084830A (ko)	2008-09-19
US7807175B2 (en)	2010-10-05
MA30252B1 (fr)	2009-03-02
ECSP088531A (es)	2008-07-30
US8603487B2 (en)	2013-12-10
NZ568384A (en)	2011-09-30

Publication	Publication Date	Title
DK1959991T3 (da)	2013-06-17	Terapeutisk vaccine
DK1968631T3 (da)	2015-06-15	Vaccine
ATE525088T1 (de)	2011-10-15	Kombinationstherapie
MA28609B1 (fr)	2007-05-02	Vaccins
DK3424932T3 (da)	2021-05-25	Bronophthalider til terapeutisk anvendelse
ATE450271T1 (de)	2009-12-15	Impfstoff
EP1868459A4 (en)	2010-01-27	FUNCTIONAL SHOE
CY2014030I1 (el)	2020-05-29	Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DK1926496T3 (da)	2013-09-30	PCV-2-vaccine
FI20060708L (fi)	2007-05-01	Hierontalaite
MA28639B1 (fr)	2007-06-01	Vaccins
EP1908389A4 (en)	2011-03-02	MEDICAL CONTROLLER
EP1917040A4 (en)	2012-12-12	VACCINE VERSATILE
DE502005007353D1 (de)	2009-07-09	Zervikale zwischenwirbelprothese
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
CR10571A (es)	2009-05-14	Vacuna virica recombinante
DK2035369T3 (da)	2014-10-06	Terapeutiske
DK1957073T3 (da)	2014-05-12	Lægemiddel
BRPI0613622A2 (pt)	2017-05-02	dispositivo médico
BRPI0607474A2 (pt)	2016-11-01	vacinação enriquecida com glicosido-alquila
MA28885B1 (fr)	2007-09-03	vaccins
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
DE602006020744D1 (de)	2011-04-28	Fertigspritze
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802